Dr Aditya Bardia spoke to ecancer online about the the randomised phase 3 ASCENT study of sacituzumab govitecan vs treatment of physician’s choice in patients with previously treated metastatic triple-negative breast cancer (mTNBC) he presented at the virtual ESMO 2020.
He explains that the study met its primary endpoint and that patients who received sacituzumab govitecan had a median progression free survival of 5.6 months compared with 1.7 months for patients on standard chemotherapy.
In terms of overall survival, Dr Bardia reported that patients who received sacituzumab govitecan had an overall survival of 12.1 months compared with 6.7 months to those on standard chemotherapy.
Read related news here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.